JAMA Surg: Bear deoxycholic acid for prevention of gallstones after gastric cancer removal

Statistics found that the incidence of gallstones increased in patients after gastric resection, and researchers recently examined the effectiveness and safety of the formation of gallstones after gastric resection in patients with theofgastric cancerThe PEGASUS-D study was conducted in 12 hospitals in South Korea and was conducted in randomized, double-blind, placebo-controlled clinical trialsAdults with gastric cancer (age 19 years) were involved, and patients underwent a full gastric excision, a far-end gastric excision, or a near-end gastric excision, and randomly received 300 mg of UDCA, 600 mg of UDCA or placebo for 52 weeksDuring the follow-up period, every 3 months abdominal ultrasound examination of the formation of gall (knot) stone, the main endpoint is the proportion of patients with gall (knot) stone within 12 months after gastric removala total of 521 patients (175 received 300 mg UDCA, 178 received 600 mg UDCA, and 168 received a placebo) participating in the studyThe full analysed data set included 465 patients (311 males; median age, 56.0 years of age), of which 151 patients in the 300 mg UDCA group, 164 patients in the 600 mg UDCA group and 150 patients in the placebo groupThe proportion of patients with gallbladder (knot) stone within 12 months of gastric resection was: 8 out of 151 in the 300 mg UDCA group (5.3%), 7 (4.3%) in 164 cases in the 600 mg UDCA group, and 25 (16.7%) in 150 cases in the placebo groupCompared to the placebo group, the risk ratio of gallstone formation in the 300 mg UDCA group was 0.27,600 mg group was 0.20No significant adverse drug reactions were found in the patients involved in the studystudy suggests that 12-month bear deoxycholic acid treatment can significantly reduce the incidence of gallbladder after gastric cancer removal